I'm not sure it's the US$ depreciation that's causing the...

I'm not sure it's the US$ depreciation that's causing the rot.

AAH is a drug discovery and IP company. These things take time - lots of time, hence there is a large risk associated with this company. At the present time, the market is shying away from everything risky, including AAH.

In the past, this company has delivered the goods - the Domantis investment is the most obvious, but their royalty streams from existing patents are also not to be sneezed at.

I too was disappointed when the merger with Evogenix caused the SP to drop by 50%. From what I understand, this is a good fit. I was also disappointed when the pipeline seemed rather thin, post-merger. This is my biggest concern actually.

However, what it comes down to is this. If their current drug development projects are successful, they'll generate substantial income. At that point, the SP will fly. Otherwise, it'll just slide.

Cheers,

BB